Samsara BioCapital’s Sutro Biopharma STRO Stock Holding History

Samsara BioCapital’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.3M	Hold	1,062,872	–	–	2.9%	9
2026 Q1	$26.5M	Buy	1,062,872 +858,369	+420%	+$15.5M	2.57%	9
2025 Q4	$2.37M	Sell	204,503 -15,178	-7%	-$144K	0.24%	19
2025 Q3	$1.91M	Hold	219,681	–	–	0.25%	23
2025 Q2	$1.57M	Hold	219,681	–	–	0.32%	22
2025 Q1	$1.43M	Hold	219,681	–	–	0.25%	23
2024 Q4	$4.04M	Hold	219,681	–	–	0.55%	26
2024 Q3	$7.6M	Hold	219,681	–	–	1.46%	18
2024 Q2	$6.44M	Buy	219,681 +52,123	+31%	+$2.06M	1.35%	19
2024 Q1	$9.47M	Hold	167,558	–	–	1.46%	17
2023 Q4	$7.19M	Hold	167,558	–	–	1.12%	17
2023 Q3	$5.81M	Hold	167,558	–	–	1.78%	15
2023 Q2	$7.79M	Hold	167,558	–	–	1.37%	13
2023 Q1	$7.74M	Hold	167,558	–	–	1.6%	15
2022 Q4	$13.5M	Hold	167,558	–	–	2.91%	9
2022 Q3	$9.3M	Hold	167,558	–	–	2.17%	11
2022 Q2	$8.73M	Hold	167,558	–	–	2.33%	11
2022 Q1	$13.8M	Hold	167,558	–	–	3.47%	9
2021 Q4	$24.9M	Hold	167,558	–	–	4.84%	5
2021 Q3	$31.7M	Hold	167,558	–	–	4.97%	6
2021 Q2	$31.1M	Hold	167,558	–	–	3.85%	8
2021 Q1	$38.1M	Hold	167,558	–	–	7.03%	5
2020 Q4	$36.4M	Hold	167,558	–	–	3.66%	5
2020 Q3	$16.8M	Hold	167,558	–	–	4.7%	6
2020 Q2	$13M	Buy	167,558 +55,000	+49%	+$5.28M	4.18%	9
2020 Q1	$11.5M	Hold	112,558	–	–	6.61%	6
2019 Q4	$12.4M	Hold	112,558	–	–	5.93%	6
2019 Q3	$10.2M	Hold	112,558	–	–	6.96%	7
2019 Q2	$12.8M	Hold	112,558	–	–	8.46%	5
2019 Q1	$12.8M	Hold	112,558	–	–	10.08%	5
2018 Q4	$10.2M	Buy	+112,558	New	+$13.6M	9.75%	4

Other funds holding STRO

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Samsara BioCapital's STRO Position: Q2 2026 in Review

Samsara BioCapital held its Sutro Biopharma (STRO) position steady in Q2 2026 at 1,062,872 shares worth $35.3M. The position accounts for 2.9% of the portfolio, ranked #9.

Samsara BioCapital first reported a position in STRO in Q4 2018 and has held it in 31 quarters since. The position peaked at $38.1M in Q1 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

Samsara BioCapital held 1,062,872 shares of Sutro Biopharma worth $35.3M as of Q2 2026.
Samsara BioCapital left its Sutro Biopharma share count unchanged in Q2 2026.
Sutro Biopharma made up 2.9% of Samsara BioCapital's portfolio in Q2 2026, its #9 holding.
Samsara BioCapital first reported a position in Sutro Biopharma in Q4 2018 and has held it in 31 quarters since.
Samsara BioCapital's Sutro Biopharma position peaked at $38.1M in Q1 2021.
100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Samsara BioCapital's 13F filing for Q2 2026, filed 14 Aug 2026.